“Before you begin treatment, you should feel good knowing that you have done your due diligence, you are confident that you have received the correct diagnosis, and you are comfortable with your medical team and your treatment plan,” says Dr. Frederick.
Not all patients respond to all types of immunotherapies. So how can doctors identify which treatments have the best chance of working in a specific patient? How can they quickly zero in on the best options on a list of immunotherapies that grows longer every day?
The report released yesterday by the Cancer Moonshot Blue Ribbon Panel, a group convened by Vice President Biden last winter, highlighted some big ideas and high-impact opportunities in oncology.